Nectar Lifesciences Limited, an integrated pharmaceutical company, primarily engages in the development, manufacture, and marketing of various active pharmaceutical ingredients (APIs) and finished dosage forms in India and internationally. Its APIs and intermediates include cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCL, cefepime HCL, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company's finished dosage forms consist of tablets, capsules, dry powder oral suspension, and granules and injectibles. It also offers contract research and manufacturing services, such as process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, pilot plant production, bulk production, and Chiral resolution, as well as provides chemical and analytical development services. In addition, the company offers generic and OTC products, empty hard gelatin capsules, and diagnostics products; and manufactures menthol and allied products, including menthol crystals, menthol flakes, peppermint oil, mentha piperita, Indian spearmint oil, menthones, mint blends, dementholised peppermint oil, and mint based products.